AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1000228
Drug: Radiant heater
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiant heater group (babies < 1500 g)
Trial: 1000228
Drug: Radiant heater
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiant heater group (babies < 1000 g)
Trial: 1000228
Drug: Incubator group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incubator group (babies < 1000 g)
Trial: 31511286
Drug: Short interval
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short interval (<3 years) between menarche and first sexual intercourse (FSI) or start of oral contraceptive (OC) use
Trial: 28608926
Drug: Flibanserin 100
RxNorm normalized name: flibanserin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flibanserin 100 mg plus ethanol 0.4 g/kg
Trial: 28608926
Drug: Flibanserin 100
RxNorm normalized name: flibanserin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flibanserin 100 mg plus ethanol 0.8 g/kg
Trial: 22248038
Drug: Flibanserin 100
RxNorm normalized name: flibanserin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flibanserin 100 mg
Trial: 28608926
Drug: Flibanserin 100
RxNorm normalized name: flibanserin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flibanserin 100 mg plus ethanol
Trial: 26392753
Drug: Sibutramine (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (daily 12.55 mg)
Trial: 21649532
Drug: Fermented milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented milk product containing Ile-Pro-Pro and Val-Pro-Pro (25 mg peptides and 2 g plant sterols)
Trial: 17129925
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment (cyclobenzaprine)
Trial: 17129925
Drug: Combined pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined pharmacological and cognitive-behavioral treatment
Trial: 14715848
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (1 mg/d 17beta‐estradiol combined with norethisterone acetate)
Trial: 11692292
Drug: Rifaximin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin (400 mg twice per day)
Trial: 11692292
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg twice per day)
Trial: 3110804
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g L-carnitine daily for 3 weeks
Trial: 3110804
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g L-carnitine single oral dose
Trial: 29729237
Drug: Melatonin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (3 mg nightly)
Trial: 28760798
Drug: Elastomeric infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elastomeric infusion pump (Baxter Infusor)
Trial: 28760798
Drug: Electronic infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electronic infusion pump (ambIT Continuous)
Trial: 22946487
Drug: Metyrapone (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metyrapone (750 mg) with MDMA (75 mg)
Trial: 8144852
Drug: Metyrapone (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metyrapone (750 mg)
Trial: 15750189
Drug: 600-mg clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600-mg clopidogrel loading dose
Trial: 15750189
Drug: 300-mg clopidogrel
RxNorm normalized name: clopidogrel 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-mg clopidogrel loading dose
Trial: 18400718
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acid eicosapentaenoic acid (EPA) capsules (1.5 g/d) for 6 months
Trial: 18400718
Drug: No supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplement (controls)
Trial: 17409863
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (100 mg/m for 3 of 4 weeks) and carboplatin (AUC = 6 mg/ml/min once every 4 weeks)
Trial: 17409863
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel or observation as maintenance therapy after four cycles of chemotherapy
Trial: 10776684
Drug: Mud packs
RxNorm normalized name: aminophylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Tablet [Mudrane GG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud packs and sulfur baths in addition to daily exposure to sun ultraviolet rays and regular bathing at the Dead Sea (Group 1)
Trial: 10776684
Drug: Daily exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily exposure to sun ultraviolet rays and regular bathing at the Dead Sea (Group 2)
Trial: 8737630
Drug: Oxerutins (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxerutins (2 x 500 mg daily)
Trial: 1568584
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg MK-329
Trial: 31822925
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of vaporized synthetic 5‐methoxy‐N,N‐dimethyltryptamine
Trial: 21189766
Drug: Prop‐based oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prop‐based oral health and nutrition intervention program (8‐10 minute duration)
Trial: 15955217
Drug: Terlipressin 2
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin 2 mg after somatostatin 250 microg/h
Trial: 8679357
Drug: 0.5% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% lignocaine 3 mg kg‐1
Trial: 2049321
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (RT + MVPP)
Trial: 6344698
Drug: Innovar, 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovar, 0.1 ml/kg, intravenously
Trial: 6344698
Drug: Morphine, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine, 0.5 mg/kg, intravenously
Trial: 19155896
Drug: 17 alpha‐hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 alpha‐hydroxyprogesterone caproate (250 mg, weekly intramuscular injections starting at 16-20 weeks until delivery or 35 weeks)
Trial: 19155896
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching injections, same schedule as intervention)
Trial: 15567936
Drug: Single-agent docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-agent docetaxel (T)
Trial: 15567936
Drug: Single-agent doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent doxorubicin (A)
Trial: 6788275
Drug: Naftidrofuryl infusion
RxNorm normalized name: naftidrofuryl
DrugBank: Naftidrofuryl (DB13588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl infusion
Trial: 24412801
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg DKP
Trial: 24412801
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg DKP
Trial: 22333955
Drug: Classification-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classification-based treatment approach
Trial: 22258622
Drug: Usual physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual physical therapy care
Trial: 17071953
Drug: Branded drugs
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded drugs
Trial: 14687051
Drug: Misoprostol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (25 mcg, hospital-prepared capsule)
Trial: 14687051
Drug: Dinoprostone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone (1 mg gel)
Trial: 10723516
Drug: Stavudine-based multiple
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stavudine-based multiple agent combinations (including protease inhibitor-containing and -sparing regimens, triple nucleoside RTI regimens, and regimens including non-nucleoside RTIs and/or hydroxyurea)
Trial: 10723516
Drug: Stavudine-based multiple
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stavudine-based multiple agent combinations
Trial: 7712309
Drug: Interferon-alpha (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (5 MU daily for 6 months)
Trial: 7712309
Drug: Interferon-alpha (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (5 MU three times per week or daily for 6 months)
Trial: 31178940
Drug: High medication
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High medication necessity belief
Trial: 31178940
Drug: Negative belief
RxNorm normalized name: Ora Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative belief toward medications
Trial: 31178940
Drug: Low medication
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low medication necessity belief
Trial: 31178940
Drug: High medication
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High medication concern belief
Trial: 30478263
Drug: Negative medication
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative medication belief
Trial: 31178940
Drug: Nonadherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonadherence to medications
Trial: 26565077
Drug: Dalfampridine ER
RxNorm normalized name: Dalfampridine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalfampridine ER 10 mg BID
Trial: 26565077
Drug: Dalfampridine ER
RxNorm normalized name: Dalfampridine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalfampridine ER 5 mg BID
Trial: 23563245
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (1.7 g DHA and 0.6 g EPA)
Trial: 17078155
Drug: Losartan-based antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan-based antihypertensive treatment
Trial: 19407804
Drug: Atenolol-based antihypertensive
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol-based antihypertensive treatment
Trial: 17956497
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg sulphadoxine/2.5 mg pyrimethamine
Trial: 7754939
Drug: Enalapril treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril treatment initiated < 24 hours after AMI
Trial: 2279540
Drug: no further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no further treatment (control group)
Trial: 6793924
Drug: Acetylsalicylate of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylsalicylate of lysine (1.8 g)
Trial: 6793924
Drug: Acetylsalicylate of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylsalicylate of lysine (3.6 g)
Trial: 375401
Drug: Pentazocine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (60 mg)
Trial: 26303134
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 500 μg BID for 8 weeks
Trial: 23525738
Drug: High-dose sevoflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sevoflurane (1.5 MAC)
Trial: 23525738
Drug: Moderate-dose sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate-dose sevoflurane (1.0 MAC)
Trial: 23525738
Drug: Low-dose sevoflurane
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sevoflurane (0.5 MAC)
Trial: 21488754
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of English walnuts per day for 30 days
Trial: 21488754
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of black walnuts per day for 30 days
Trial: 15923688
Drug: Nutrition education
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition education intervention delivered monthly by trained counsellors
Trial: 11973440
Drug: Oral 17beta-estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 2.5 mg daily
Trial: 11973440
Drug: Oral 17beta-estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 5 mg daily
Trial: 11973440
Drug: Oral 17beta-estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 10 mg daily
Trial: 11973440
Drug: Oral 17beta-estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 20 mg daily
Trial: 11973440
Drug: Oral 17beta-estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 2.5 to 20 mg daily
Trial: 9819446
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with interferon alfa-2b and ribavirin (1000 or 1200 mg orally per day) for 24 weeks
Trial: 9819446
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with interferon alfa-2b and ribavirin (1000 or 1200 mg orally per day) for 48 weeks
Trial: 9819446
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy for 24 weeks
Trial: 9819446
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy for 48 weeks
Trial: 8961
Drug: Single intracarotid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intracarotid injection of phenoxybenzamine
Trial: 8961
Drug: Prolonged treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged treatment with propranolol
Trial: 28545564
Drug: Sufentanil 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 1.0 μg ml‐1 plus dexmedetomidine 4 μg ml‐1 (Group SD)
Trial: 28545564
Drug: Sufentanil 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 1.0 μg ml‐1 (Group S)
Trial: 25213114
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy-based programme
Trial: 24376277
Drug: Behavioral support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral support sessions plus 7 weeks of bupropion therapy (BSS+)
Trial: 21566568
Drug: Erythromycin (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (12.5 mg kg(‐1) per day)
Trial: 21566568
Drug: UDCA (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA (5 mg kg(‐1) every 6 h)
Trial: 17449575
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate (NaH, 300 mg)
Trial: 17449575
Drug: Chondroitin sulfate
RxNorm normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulfate (CS, 360 mg)
Trial: 24938324
Drug: Propranolol at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol at 80 mg/day plus HFA-BDP at 100 μg/day
Trial: 24938324
Drug: HFA-BDP at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA-BDP at 400 μg/day
Trial: 22874535
Drug: Potassium nitrate
RxNorm normalized name: Potassium Nitrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potassium nitrate (614-mg nitrate)
Trial: 19337557
Drug: Omega-3 PUFAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFAs plus rosuvastatin 10 mg
Trial: 19337557
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg alone
Trial: 19337557
Drug: Omega-3 PUFAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFAs added to rosuvastatin 10 mg
Trial: 16250069
Drug: Olanzapine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (2.5 to 7.5 mg/d)
Trial: 16250069
Drug: Olanzapine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (2.5 to 7.5 mg/d) in patients with MMSE scores of 14-18 (n = 35)
Trial: 16250069
Drug: Olanzapine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (2.5 to 7.5 mg/d) in patients with MMSE scores of 23-26 (n = 78)
Trial: 10229732
Drug: GV150526 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GV150526 (800 mg loading dose followed by 400 mg BID maintenance)
Trial: 10229732
Drug: GV150526 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GV150526 (200 mg BID maintenance)
Trial: 8916624
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy (CT) and Interpersonal Therapy (IPT)
Trial: 6871083
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg almitrine
Trial: 6871083
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg almitrine
Trial: 24957863
Drug: Mosapride 5
RxNorm normalized name: mosapride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride 5 mg thrice daily plus Omeprazole 10 mg once daily (GO group)
Trial: 19174703
Drug: Gemfibrozil (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil (600 mg twice a day) plus American phase 3 diet for 2 months
Trial: 17438705
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment (chemotherapy)
Trial: 15975358
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel therapy with intraoperative aprotinin
Trial: 15975358
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 5 days before surgery and placebo infusions intraoperatively
Trial: 10357038
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly ECT
Trial: 9821454
Drug: High stimulus
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High stimulus dose with once weekly ECT
Trial: 7714075
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg melatonin (1 mg at 0800, 1000, and 1200 h)
Trial: 2845199
Drug: Deferoxamine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferoxamine (30 mg/kg IV before and after bypass, 250 mg/L in cardioplegic solution)
Trial: 31621901
Drug: Intervention (INT)
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention (INT) - Geriatric Acute and Post-Acute Fall Prevention Intervention (GAPcare) including medication therapy management by a pharmacist and fall risk assessment by a physical therapist.
Trial: 31337525
Drug: Catheter ablation
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter ablation (CA) with anticoagulant therapy using edoxaban
Trial: 14518608
Drug: L-arginine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (8 g p.o. two times daily) for 14 days
Trial: 14518608
Drug: L-arginine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (8 g p.o. two times daily)
Trial: 14518608
Drug: L-arginine and
RxNorm normalized name: Amino Acid, Amino Acids 5% (L-Arginine and L-Lysine) intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine and placebo
Trial: 10830415
Drug: tolcapone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolcapone (50 mg, 200 mg, or 400 mg three times a day)
Trial: 9014744
Drug: Intravenous clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous clodronate (1800 mg) combined with MivP chemotherapy